CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Mycophenolate sodium

Last Updated: March 3, 2005
Result type: Reports
Project Number: S0034
Product Line: Reimbursement Review

Generic Name: Mycophenolate sodium

Brand Name: Myfortic

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Organ rejection in allogeneic renal transplants, Prophylaxis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 8, 2005

Recommendation Type: List in a similar manner to other drugs in class